Group 1: Company Overview - The main business of the company is focused on the diagnostic field [2] - The independent laboratory operated well in 2015, showing a slight surplus [3] - The profit structure mainly consists of operating income and non-operating income, with non-operating income primarily from investment returns [3] Group 2: Business Model and Investment - The company is currently engaged in a broad industrial chain layout, including clinical diagnostic services, independent laboratories, incubators, and hospitals [3] - The company primarily invests in public hospitals due to their more standardized management and richer medical resources [4] - There is no specific investment quantity planned for hospital investments as it is still in the early stages, with future plans dependent on development models and national policy [4] Group 3: Future Considerations - The company will consider suitable targets for investment within Guangdong Province based on project feasibility [4] - The hospital investment business is a key development direction for the company moving forward [4]
达安基因(002030) - 2016年4月12日投资者关系活动记录表